^
    Back
    Association details:
    Biomarker:MFI2 expression
    Cancer:Triple Negative Breast Cancer
    Drug:SGN-CD228A (Microtubule inhibitor, CD228-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 2888: Utilizing PDX models to better understand factors that predict response to SGN-CD228A, an antibody drug-conjugate (ADC) for solid tumors

    Published date:
    05/15/2020
    Excerpt:
    In this study, we included models that have a wide range of CD228 expression as assessed by RNA seq, IHC, mass spectrometry, and western blotting. Of the three tumor types tested, TNBC appeared to be the most sensitive, with 59% of the models achieving >30% tumor volume reduction.
    DOI:
    10.1158/1538-7445.AM2020-2888